|
2024
|
Invention
|
Cardioprotective lipids and methods of use. The present invention includes a method of reducing o... |
|
2023
|
Invention
|
Dosing regimens for treatment of proliferative disorders.
The present invention includes composi... |
|
|
Invention
|
Cardioprotective lipid and method of use. The present invention includes a method of reducing or ... |
|
|
Invention
|
Cardioprotective lipids and methods of use.
The present invention includes a method of reducing ... |
|
2022
|
Invention
|
Cardioprotective lipid and method of use.
The present invention includes a method of reducing or... |
|
|
Invention
|
Treatment for malignant pleural effusion in humans.
The present invention includes method for tr... |
|
|
Invention
|
Treatment for malignant pleural effusion in humans. The present invention includes method for tre... |
|
|
Invention
|
Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokine... |
|
2021
|
Invention
|
Cardiopathy-reducing phosphodiester lipids. The present invention includes compound having the fo... |
|
|
Invention
|
Suppression of cytokine release and cytokine storm. The present invention includes methods and co... |
|
2020
|
Invention
|
Suppression of cytokine release and cytokine storm.
The present invention includes methods and c... |
|
2019
|
Invention
|
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel.
Compositions and met... |
|
|
Invention
|
Treatment for glioblastoma.
The present invention includes a composition and method for treating... |
|
|
Invention
|
Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopa... |
|
|
Invention
|
Novel lipids. The present invention includes compound having the following structural formula: (I). |
|
|
Invention
|
Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current.
C... |
|
|
Invention
|
Kr channel. Kr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-... |
|
|
Invention
|
Dosing regimens for treatment of proliferative disorders. The present invention includes composit... |
|
2018
|
Invention
|
Compositions and method for reducing cardiotoxicity. The present invention includes composition a... |
|
|
Invention
|
Compositions and method for reducing cardiotoxicity.
The present invention includes composition ... |
|
|
Invention
|
Liposomal curcumin for treatment of diseases.
The present invention provides compositions and me... |
|
2017
|
Invention
|
Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current. Co... |
|
|
Invention
|
Prevention of drug-induced atrio-ventricular block. The present invention includes a method of tr... |
|
|
Invention
|
Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma. The present i... |
|
|
Invention
|
Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma.
The present ... |
|
2016
|
Invention
|
Treatment for glioblastoma. The present invention includes a composition and method for treating ... |
|
|
Invention
|
Curcumin for treating intervertebral disc disease.
The present invention includes a method of tr... |
|
2015
|
Invention
|
Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tet... |
|
|
Invention
|
Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause chan... |
|
|
Invention
|
Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for c... |
|
2014
|
Invention
|
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel. Compositions and meth... |
|
|
Invention
|
Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders.
Compos... |
|
|
Invention
|
Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders. Composi... |
|
|
Invention
|
Liposomal curcumin for treatment of diseases. The present invention provides compositions and met... |
